New patent for the use of estrogens in the treatment of DED to be issued in the US
The US Patent and Trademark Office has issued a notice of allowance indicating that a new patent will be granted to Redwood Pharma regarding the use of estrogens in the treatment of dry eye disease. When officially received, this patent will serve as another critical cornerstone in Redwood Pharma’s patent portfolio.This new patent will complement existing patent protection of RP101 including the use of IntelliGel in the US. As such, Redwood Pharma’s estrogen therapies will have thorough protection through both the exclusive use of active substance and drug delivery system. “In March of